A nome dei nostri membri, SMOB ha inviato una lettera aperta al BAG per richiamare l’attenzione sui problemi attuali relativi all’attuazione dell’elenco delle specialità di Wegovy®. L’obiettivo è garantire l’assistenza medica ai pazienti affetti da obesità.
MoreBernd Schultes1, Marco Bueter2,3, Lucie Favre4,5,6, Katharina Timper7,8 for the collaborative task force “prioritization of anti-obesity pharmacotherapy” of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB) Background The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product Wegovy® (2.4 mg semaglutide) demands a prioritization by means of which […]
MoreTo our Patients,To the loved ones of people living with obesity,To our Colleagues in healthcare, Obesity care has seen considerable improvements in the past years. Pharmacotherapy and bariatric-metabolic surgery can now offer several treatment options that are secure and efficient.However, as it often happens when medical progress evolves fast, good practice recommendations and treatments with […]
More